Galmed Pharmaceuticals Holds Shareholder Meeting
Ticker: GLMD · Form: 6-K · Filed: Aug 15, 2025 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Aug 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing-update
TL;DR
Galmed Pharma held its shareholder meeting on Aug 15th, voting on a proposal from the July 24th proxy.
AI Summary
On August 15, 2025, Galmed Pharmaceuticals Ltd. held a Special General Meeting of Shareholders where shareholders voted on a proposal previously detailed in a proxy statement filed on July 24, 2025. The specific outcome of this vote is not detailed in this filing.
Why It Matters
Shareholder meetings are crucial for corporate governance, allowing investors to vote on important company matters and influence strategic decisions.
Risk Assessment
Risk Level: low — This filing is a routine report of a shareholder meeting and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Registrant
- August 15, 2025 (date) — Date of Shareholder Meeting
- July 24, 2025 (date) — Date of Proxy Statement Filing
FAQ
What was the specific proposal voted on at the August 15, 2025 Special General Meeting of Shareholders?
The filing states that shareholders voted on a proposal described in the proxy statement filed on July 24, 2025, but does not specify the nature of the proposal itself.
What was the outcome of the shareholder vote on August 15, 2025?
This Form 6-K filing reports that the meeting was held and a vote took place, but it does not disclose the results of that vote.
Where can I find details about the proposal discussed at the shareholder meeting?
Details about the proposal are available in the proxy statement filed by Galmed Pharmaceuticals Ltd. with the SEC on July 24, 2025.
What is the exact name of the company filing this report?
The exact name of the company is Galmed Pharmaceuticals Ltd.
What type of report is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
Filing Stats: 303 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2025-08-15 16:05:24
Filing Documents
- form6-k.htm (6-K) — 19KB
- ex99-1.htm (EX-99.1) — 341KB
- 0001641172-25-024365.txt ( ) — 361KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: August 15, 2025 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer